(+)-PD 128907 hydrochloride
Potent D3 dopamine receptor agonist (Ki = 2.3 nM). Displays 18 - 200-fold selectivity over other dopamine receptor subtypes.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 10 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 285.77. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.5 mL||17.5 mL||34.99 mL|
|5 mM||0.7 mL||3.5 mL||7 mL|
|10 mM||0.35 mL||1.75 mL||3.5 mL|
|50 mM||0.07 mL||0.35 mL||0.7 mL|
References are publications that support the products' biological activity.
Bristow et al (1996) The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology 35 285 PMID: 8783203
Pugsley et al (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J.Pharmacol.Exp.Ther. 275 1355 PMID: 8531103
Witkin et al (1998) Atypical antipsychotic-like effects of the dopamine D3 receptor agonist (+)-PD 128907. Eur.J.Pharmacol. 347 R1 PMID: 9741997
If you know of a relevant reference for (+)-PD 128907 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: (+)-PD 128907 hydrochloride, supplier, D3, agonists, D2, D4, Dopamine, Receptors, dopaminergic, (+)-PD128907, hydrochloride, PD128907, D3, Receptors, D3, Receptors, Tocris Bioscience
6 Citations for (+)-PD 128907 hydrochloride
Citations are publications that use Tocris products. Selected citations for (+)-PD 128907 hydrochloride include:
Schulz et al (2012) First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol 167 1480 PMID: 22817643
Marcellino et al (2008) Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. Neurosci Lett 283 26016 PMID: 18644790
Zapata et al (2007) Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem 282 35842 PMID: 17923483
Zhang et al (2004) Cocaine-induced intracellular signaling and gene expression are oppositely regulated by the dopamine D1 and D3 receptors. J Neurosci 24 3344 PMID: 15056714
Clemens and Hochman (2004) Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 24 11337 PMID: 15601940
Cote and Kuzhikandathil (2015) Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease. J Neurosci 585 33 PMID: 25445374
Do you know of a great paper that uses (+)-PD 128907 hydrochloride from Tocris? If so please let us know.
(+)-PD 128907 hydrochloride Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.